{"id":573267,"date":"2025-09-26T00:00:00","date_gmt":"2025-09-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2025-biopharma-psoriasis-disease-landscape-forecast-g7-2025\/"},"modified":"2026-03-31T10:24:55","modified_gmt":"2026-03-31T10:24:55","slug":"dlsfim0005-2025-biopharma-psoriasis-disease-landscape-forecast-g7-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2025-biopharma-psoriasis-disease-landscape-forecast-g7-2025\/","title":{"rendered":"Psoriasis | Disease Landscape &#038; Forecast | G7 | 2025"},"content":{"rendered":"<p>The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly\u2019s Taltz, Johnson &#038; Johnson Innovative Medicine\u2019s Tremfya, AbbVie\u2019s Skyrizi) are fiercely competing with the established agents Humira and Stelara, effectively earning a strong position in a crowded market due to their greater efficacy, more-convenient dosing, and faster onset of action. The availability of BMS\u2019s oral TYK2 inhibitor Sotyktu and UCB\u2019s IL-17 A\/F dual inhibitor Bimzelx has expanded dermatologists\u2019 treatment armamentarium and increased competition among targeted therapies. Moreover, several oral\u2014and thus more-convenient\u2014agents for psoriasis, including piclidenoson, which has a novel mechanism of action, are expected to launch, further fueling competition in this space. Nevertheless, substantial unmet need in the treatment of psoriasis remains (e.g., agents that induce long-term remission for patients with severe disease, more-affordable therapies for patients with mild disease).<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq \/ Lumicef, Bimzelx) and the IL-23 inhibitors (Tremfya, Ilumya, Skyrizi), and where are \/ will these agents be positioned in the psoriasis treatment algorithm?<\/li>\n<li>How is the oral TYK2 inhibitor Sotyktu affecting apremilast\u2019s (Amgen\u2019s Otezla) patient share, and how do the two agents compare on efficacy and safety attributes?<\/li>\n<li>How does the availability of adalimumab biosimilars in the United States impact the psoriasis market?<\/li>\n<li>What unmet needs remain in the treatment of psoriasis? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events. \u200b\u200b\u200b\u200b\u200b<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-573267","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573267\/revisions"}],"predecessor-version":[{"id":575729,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573267\/revisions\/575729"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}